Combo Treatment Provides Relief

Published Online: Tuesday, March 1, 2005

A Canadian study of 2760 patients with asthma at 246 centers in 22 countries found that combining an inhaled corticosteroid and a long-lasting beta-2 agonist appeared to provide consistent relief for individuals with asthma. Specifically, there was a 45% lower exacerbation rate with the combined budenoside/formoterol therapy. The treatment also lowered overall severe exacerbation levels and delays in exacerbations requiring medical attention, improved lung function, reduced awakenings at night because of disease, and improved symptom control. (The findings were reported in the American Journal of Respiratory and Critical Care Medicine, January 2005).

Latest Articles
Pharmacies are rated as some of the best places to receive top-notch customer service in America.
Often caused by acid reflux, eosinophilic esophagitis is an emerging inflammatory disease that is generally unresponsive to proton pump inhibitor therapy.
Carlos Aquino, founder and president of PharmaDiversion LLC, discusses timing of inspections from the Drug Enforcement Administration.
The FDA has again rejected AMAG Pharmaceuticals’ application for a single-dose version of hydroxyprogesterone caproate injection (Makena) to reduce the risk of preterm birth for at-risk women.
Latest Issues